Ultrasound Spectroscopy as Early Indicators of Radiation Treatment Response in Prostate, Rectum and Head & Neck Cancers

Inclusion Criteria:

* (1) Histologically or cytologically confirmed prostate, rectum and head and neck carcinoma which has not been treated with any first-line therapy and will be treated with radiation therapy
* (2) Measurable disease by ultrasound, or MRI performed within 28 days prior to treatment
* (3) Eastern Co-operative Oncology Group (ECOG) Performance Status of 0 or 1
* (4) Life expectancy of at least 6 months
* (5) Adequate bone marrow, liver and renal function as assessed by the following laboratory requirements to be conducted within 7 days prior to dosing:

  (i) hemoglobin \>90 mg/dL (ii) leukocytes \>3,000/mL (iii) absolute neutrophil count \>1,500/mL (iv) platelets \>100,000/mL (v) total bilirubin within normal institutional limits (vi) AST(SGOT)/ALT(SGPT) \<2.5 X institutional upper limit of normal (vii) creatinine within normal institutional limits or creatinine clearance \>60 mL/min/1.73 m2 for patients with creatinine levels above institutional upper limit of normal
* (6) Patients should have the ability to understand and the willingness to sign a written informed consent document. Signed informed consent must be obtained prior to any study specific procedures

Exclusion Criteria:

* (1) Chemotherapy, radiotherapy, or major surgery within 4 weeks prior to registering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks prior to registration
* (2) Receiving any other investigational agents
* (3) Known brain metastases
* (4) History of allergic reactions attributed to compounds of similar chemical or biologic composition
* (5) Contraindications to radiotherapy such as but not limited to:

  (i) previous radiotherapy to an involved area (ii) active collagen vascular disease (iii) genetic diseases associated with hyper-radiosensitivity
* (6) Any clinically serious infections requiring systemic anti-bacterial, antifungal or antiviral therapy
* (7) Uncontrolled intercurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, and cardiac arrhythmia
* (8) Psychiatric illness/social situations that would limit compliance with study requirements
* (9) History of active ongoing seizure disorder, substance abuse, medical, psychological or social conditions that may interfere with the patient's participation in the study or evaluation of the study results
* (10) Any condition that is unstable or could jeopardize the safety of the patient and their compliance in the study.